I cannot do what I do without the support of Orion Peptides and the educational work they help make possible. Use code Parker15 for 15% off. One of the biggest problems in the peptide space right now is that most people have no idea how to verify what they are actually getting. And honestly, that is dangerous. A label means nothing if there is no real verification behind it. The reality is: • some vendors provide legitimate testing • some recycle old COAs • some copy documentation from completely unrelated batches • and some people never verify anything at all The good news is there are actually several ways to independently check compounds yourself without relying entirely on marketing claims. Here are three of the best tools and strategies people can use right now. 1. Janoshik: Search the Public Database One of the most useful resources available in the peptide and research compound space is the Janoshik Analytics public database. While laboratory testing itself is a paid service, the database is publicly searchable. This means researchers can: • search batch numbers • compare testing dates • verify compound identity • and check whether the reported batch actually matches the product being sold This is important because one of the oldest tricks in the industry is posting: • outdated certificates • unrelated test reports • or recycled documentation from years earlier By searching the actual batch number, you can often identify whether: • the test was recent• the batch exists publicly • and whether the documentation aligns with the product itself That level of transparency matters. 2. PubMed: Read the Actual Research Another huge mistake people make is relying entirely on: • influencers • TikTok clips • forum posts • Reddit threads • or YouTube summaries Instead of reading the actual published research. PubMed remains one of the best free scientific databases available for: • peptide mechanisms • receptor activity

Look, I know I’m not the only one who had a minor panic attack last month when the FDA dropped the hammer. If you’ve been living under a rock or just started your GLP-1 journey, here’s the TL;DR: The agency officially declared the shortage of name-brand Zepbound and Wegovy "resolved." Which, for us regular folks, translates to a massive crackdown on compounding pharmacies. For the last two years, compounders were legally allowed to whip up Tirzepatide and Semaglutide because Big Pharma couldn’t keep up with demand. Now? The music is stopping, and a lot of chairs are being pulled out from under people. I’ve spent the last 72 hours deep in the rabbit hole—reading legal dockets, talking to lab reps, and trying to figure out how to keep my protocol going without paying $1,200 a month out of pocket. Here is the brutal reality, what the ban actually means, and how we might navigate this moving forward. Disclaimer: The following information is for educational and research purposes only. The products discussed are strictly for research purposes only, and not used for human direct consumption. I am not a doctor. Do your own homework. Why This Ban is Different Than the “Scares” Before We’ve seen rumors of this ban for about six months. Usually, a compounding pharmacy would just add a vitamin (like B12 or Glycine) to the vial to bypass the patent, calling it a “customized formula.” The FDA tolerated that for a while. They aren't tolerating it now. The OFA (Outsourcing Facilities Association) lost a big legal battle recently. The courts ruled that as long as the brand-name drugs are on the “FDA Shortage List,” compounders can play. The moment they come off the list? Game over. Both Tirzepatide and Semaglutide are now officially deemed "available." What does this mean for you? Your local compounding pharmacy is probably sending out "We regret to inform you" emails as we speak. They can't legally fill your script anymore. For those of us who found a sustainable, affordable way to manage our metabolic health, this feels like getting rug-pulled by the system.